The Monday Brief — Week of Jul 13, 2026

Steel Partners has made an unsolicited cash offer of $16.75 per share to acquire InMode, challenging a CEO-led buyout proposal. The move signals confidence in InMode's Pulse 2.0 platform and strong cash-generation potential. InMode has confirmed receipt of the proposal and is evaluating it alongside the existing bid. The company projects $365M–$375M in 2026 revenue and expects Q2 results between $95.2M–$95.4M. For practice owners, this M&A activity underscores InMode's market strength—but also creates near-term uncertainty around product roadmaps, pricing, and support during a transition period.

• Watch for deal closure timeline and any changes to product strategy
• Monitor pricing and rebate terms if new ownership takes control
• Existing InMode users should lock in service agreements now

Medicare will negotiate prices on Botox and 14 other drugs in 2026—a landmark policy shift that threatens margins across the injectables category. AbbVie (Allergan Aesthetics) and Evolus have both filed material SEC events signaling aggressive pricing and loyalty moves. AbbVie's Allē loyalty program and Evolus's Jeuveau/Newtox positioning suggest both companies are bracing for margin compression by bundling rebates and incentives. For medspa owners, this is the beginning of a structural shift: expect lower wholesale costs but also lower reimbursement rates if you bill insurance, and intensified price wars in the cash-pay market.

• Audit your current Botox and filler contracts for flexibility
• Evaluate loyalty programs from Allergan and Evolus for margin recovery
• Plan for 10–15% margin pressure over the next 12–18 months

Evolus has secured an exclusive 15-year U.S. licensing agreement with IBSA to develop and commercialize Profhilo, a skin-quality injectable. The deal carries no upfront fees and positions Evolus to compete directly in the premium injectables space. Combined with Jeuveau and its Evolus Rewards program, the company is making a direct play for medspa volume. Profhilo's entry into the U.S. market adds a new product category—skin quality/biostimulation—that many practices haven't yet integrated into their menus. This is a competitive signal: expect aggressive pricing and co-marketing support from Evolus to gain medspa shelf space.

• Evaluate Profhilo's clinical profile and margin potential vs. existing skin-quality offerings
• Negotiate Evolus Rewards terms early before market saturation
• Consider bundling Jeuveau + Profhilo for patient retention

The neuromodulator landscape is crowded and growing. Galderma is advancing RelabotulinumtoxinA through U.S. regulatory review, and Daewoong's Nabota has surpassed ₩1 trillion (~$750M+) in cumulative global sales, signaling strong international traction. Hugel continues scaling manufacturing to support global demand. With seven FDA-approved neuromodulators now available and more in the pipeline, price competition is intensifying and patient choice is expanding. Millennials are adopting Botox at rates nearly matching Gen X, broadening the customer base but also fragmenting market share. Owners must differentiate on brand loyalty, outcomes, and bundled services rather than price alone.

• Stock multiple neuromodulator brands to offer patient choice
• Build loyalty through outcomes tracking and subscription models
• Educate staff on clinical differences to justify premium positioning

Cynosure Lutronic is expanding its monopolar RF platform (XERF™) across North America, capitalizing on rising demand for non-invasive skin tightening. SkinStylus® received new FDA clearance for periorbital wrinkles across all skin types. Candela's Nordlys® published peer-reviewed data in Nature's Scientific Reports showing reversal of skin's epigenetic aging signature. The fractional RF body device market alone is valued at $2.3 billion and growing. For practices, this signals strong patient demand for non-invasive body contouring—especially as GLP-1 weight-loss drugs drive post-weight-loss body contouring volume. Device competition is heating up, so negotiate multi-year service contracts and training support now.

• Audit your RF/laser portfolio for gaps in skin-tightening and body contouring
• Leverage GLP-1 patient flow for body-contouring upsells
• Lock in device pricing and support before market consolidation

L'Oréal has increased its investment in Galderma to 20% ownership, signaling confidence in the aesthetics market and accelerating consolidation at the brand level. This move reinforces Galderma's position as a major player and suggests continued investment in product innovation and market expansion. For practice owners, consolidation at the brand level typically means more resources for R&D and marketing support, but also potential price increases as companies leverage scale. Watch for bundled offerings and co-marketing campaigns from L'Oréal–Galderma partnerships targeting medspa channels.

• Monitor Galderma's product roadmap and medspa incentive programs
• Expect premium pricing on new Galderma launches backed by L'Oréal marketing
• Evaluate long-term partnerships with consolidated brands for stability

M&A, Medicare price negotiation, and aggressive competitive launches are reshaping medspa economics—lock in contracts, diversify brands, and prepare for margin pressure.